In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on Kestra Medical Technologies Ltd., with a price target of $27.00. The company’s shares closed last Tuesday at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results